Swiss drugmaker Novartis said European health regulators have approved a drug for advanced lung cancer that is intended to treat patients with a specific genetic mutation.
Zykadia, or ceritinib, is from a new class of medicines known as ALK inhibitors. It was approved in April 2014 in the United States.
It is designed for use in non-small cell lung cancer patients who have previously been treated with Pfizer’s Xalkori, another ALK inhibitor.
- Disorders & Diseases
- Public Health
- Products & Treatment
- Department Management